The company exhibits a nascent revenue profile with negligible top-line contributions, as evidenced by the $144.5K revenue reported in 2025Q2 against consistent quarterly operating losses of approximately $3.6 million.
| Sales/Revenue | 289K | 289K | 0 | 0 | -4.68M | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | 100% | - | - | - | - | - |
| Cost of Goods Sold | 287K | 561K | 488K | 406K | 361K | 218K | 203K | 76K | 0 |
| COGS % of Revenue | - | 194.12% | - | - | -7.72% | - | - | - | - |
| Gross Profit | 2K | -272K | -488K | -406K | -5.04M | -218K | -203K | -76K | 0 |
| Gross Margin % | 0.69% | -94.12% | - | - | 107.72% | - | - | - | - |
| Gross Profit Growth % | - | 44.26% | -20.2% | 91.94% | -2211.47% | -7.39% | -167.11% | - | - |
| Operating Expenses | -13.04M | 13.34M | -11.27K | 11.72M | 14.59M | 11.95M | 6.27M | 1.27M | 39.6K |
| OpEx % of Revenue | - | 4616.61% | - | - | -311.97% | - | - | - | - |
| Selling, General & Admin | 6.12M | 5.88M | 4.82M | 4.69M | 6.72M | 9.35M | 2.44M | 359K | 13.2K |
| SG&A % of Revenue | - | 2035.64% | - | - | -143.57% | - | - | - | - |
| Research & Development | 6.91M | 7.16M | 6.32K | 7.03M | 8.05M | 3.91M | 3.87M | 887K | 26.4K |
| R&D % of Revenue | - | 2478.2% | - | - | -172.17% | - | - | - | - |
| Other Operating Expenses | -4M | 297K | -4.84M | 0 | -176K | -1.31M | -44K | 25K | 0 |
| Operating Income | 13.04M | -13.61M | 11.27K | -12.13M | 14.89M | -12.17M | -6.27M | -1.27M | -39.6K |
| Operating Margin % | 4512.46% | -4710.73% | - | - | -318.36% | - | - | - | - |
| Operating Income Growth % | - | -120930.74% | 100.09% | -181.47% | 222.4% | -94.08% | -393.23% | -3109.6% | - |
| EBITDA | 13.18M | -13.16M | 11.44K | -11.73M | 15.19M | -11.95M | -6.07M | -1.2M | 0 |
| EBITDA Margin % | 4560.9% | -4555.36% | - | - | -324.6% | - | - | - | - |
| EBITDA Growth % | 210.04% | -115198.79% | 100.1% | -177.23% | 227.08% | -96.98% | -407.62% | - | - |
| D&A (Non-Cash Add-back) | 140K | 449K | 171 | 406K | 292K | 218K | 203K | 76K | 39.6K |
| EBIT | -13.04M | -13.61M | -11.27K | -11.28M | -14.98M | -16.94M | -7.16M | -4.57M | 0 |
| Net Interest Income | 120K | 55K | 173K | 308K | 4.5M | -5K | -5K | -8.99K | 0 |
| Interest Income | 120K | 64K | 173K | 318K | 4.68M | 1K | 5 | 9 | 0 |
| Interest Expense | 0 | 9K | 0 | 10K | 181K | 6K | 5K | 9K | 0 |
| Other Income/Expense | -25.68M | 394K | -22.32K | 847K | -29.87M | -4.79M | -959K | -3.3M | 0 |
| Pretax Income | -12.64M | -13.22M | -11.05K | -11.29M | -14.98M | -16.95M | -7.23M | -4.58M | -39.6K |
| Pretax Margin % | -4373.01% | -4574.39% | - | - | 320.14% | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | -6.27M | 6K | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 41.87% | -0.04% | 0% | 0% | 0% |
| Net Income | -12.64M | -13.22M | -11.05K | -11.29M | -4M | -16.96M | -7.23M | -4.58M | -39.6K |
| Net Margin % | -4373.01% | -4574.39% | - | - | 85.55% | - | - | - | - |
| Net Income Growth % | -15.75% | -119505.54% | 99.9% | -182.01% | 76.4% | -134.49% | -57.79% | -11475.76% | - |
| Net Income (Continuing) | -12.64M | -13.22M | -11.05K | -11.29M | -4M | -16.96M | -7.23M | -4.58M | -39.6K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.47 | -0.45 | -0.00 | -0.93 | -1.39 | -3.20 | -1.01 | -0.34 | -0.02 |
| EPS Growth % | 28.74% | - | 99.94% | 33.09% | 56.56% | -216.83% | -197.06% | -1583.17% | - |
| EPS (Basic) | - | -0.45 | -0.00 | -0.93 | -1.39 | -3.20 | -1.01 | -0.34 | -0.02 |
| Diluted Shares Outstanding | 26.78M | 29.62M | 18.52M | 12.1M | 10.79M | 5.31M | 7.19M | 13.51M | 1.96M |
| Basic Shares Outstanding | 26.78M | 29.62M | 18.52M | 12.1M | 10.79M | 5.31M | 7.19M | 13.51M | 1.96M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
Capital dilution and regulatory failure
According to recent financial disclosures, IINN generated $289,000 in TTM revenue, marking a transition from a pure R&D entity to early-stage pilot activity, though this figure remains negligible relative to the company's substantial operating expenses and the capital requirements of its clinical development roadmap.
The emergence of revenue in recent quarters suggests the company is beginning to monetize research partnerships or limited distribution agreements. However, this revenue is not yet indicative of a sustainable commercial trajectory and appears highly sensitive to project-based milestones rather than recurring clinical adoption.
As reported in quarterly filings, the company consistently allocates between $1.5 million and $2.1 million per quarter to R&D, reflecting a cost structure that is entirely decoupled from current revenue generation and heavily weighted toward the validation of its proprietary Augmented Respiration Technology system.
The persistent high level of R&D spending indicates that management is prioritizing clinical trial progression and regulatory compliance over near-term profitability. Investors should monitor whether these expenditures yield tangible regulatory milestones, as the current burn rate leaves little room for operational inefficiency.
Based on the provided income statement data, IINN exhibits extreme operating leverage, with quarterly operating losses consistently hovering near $3 million, highlighting a business model that currently lacks the scale to absorb its fixed overhead and development-related costs through its limited top-line contributions.
The absence of a meaningful gross profit margin suggests that the company is not yet manufacturing at a scale that allows for cost recovery. Until the company achieves a transition to high-volume production, operating losses will likely continue to track closely with R&D and SG&A spending.
With cash reserves of approximately $3.2 million against quarterly operating losses exceeding $3 million, the company's financial position appears increasingly precarious, suggesting that a dilutive capital raise may be required in the near term to sustain its ongoing clinical and regulatory development efforts.
The current cash-to-burn ratio warrants significant caution, as it implies a very limited runway for the company to achieve its next major value-inflection point. Any delay in regulatory clearance could force management to seek financing under potentially unfavorable terms, further impacting shareholder equity.
Quick answers to the most common questions about buying IINN stock.
For fiscal year 2025, Inspira Technologies OXY B.H.N. Ltd. (IINN) reported total revenue of $0.3M.
Inspira Technologies OXY B.H.N. Ltd. (IINN) reported a net loss of $13.2M for the fiscal year ending 2025.
Inspira Technologies OXY B.H.N. Ltd. (IINN) reported an operating income of $-13.6M, resulting in an operating profit margin of -4710.7%. This margin reflects the operational efficiency of the business before interest and taxes.
Inspira Technologies OXY B.H.N. Ltd. (IINN) generated $-0.3M in gross profit for the year, representing a gross profit margin of -94.1%. This demonstrates the company's core pricing power and production efficiency.